Black Seed (Nigella sativa L.): An Encyclopedic Reference
1. Identity and Botanical Classification
Taxonomy and Nomenclature
Nigella sativa (black seed or black cumin), which belongs to the Ranunculaceae family, is an annual herb with many pharmacological properties. The genus name Nigella is a diminutive of the Latin niger, meaning "black," referring to the colour of the seeds; the specific epithet sativa means "cultivated."
In food preparation, Nigella sativa and its seeds are variously called black caraway, black seed, black cumin, charnushka, fennel flower, nigella, nutmeg flower, Roman coriander, or black onion seed. In South Asian culinary and Ayurvedic traditions it is widely known as kalonji. Its many uses have earned Nigella the Arabic approbation Habbatul barakah, meaning "the seed of blessing."
Botanical Description and Distribution
N. sativa is an annual herbaceous plant indigenous to southern Europe, North Africa, and Southwest Asia, and is cultivated in many countries around the world such as India, Pakistan, Turkey, Ethiopia, Yemen, and Saudi Arabia. It is native to a region from eastern Europe (Bulgaria and Romania) to West Asia, and has been introduced for cultivation across Europe, Russia, India, and North Africa. The plant grows to 20–30 cm tall, with finely divided, linear leaves.
Common Forms and Preparations
Black seed can be used in various forms — whole, as an oil, in a capsule, and as a powder. It is consumed as whole seeds, ground powder, extracted oil, or as a spice. Black seeds are used as a spice in several culinary traditions, including Indian cuisine (added to curries, dal, and naan bread), Turkish cuisine (sprinkled on flatbreads and pastries), Ethiopian cuisine (used in the berbere spice blend), Persian cuisine (incorporated into yogurt, pickles, sauces, and salads), and Middle Eastern cuisine (used in various savory dishes and as a garnish).
Commercial supplement forms include powder, tablets, sprays, gels, creams, shampoos, soaps, oils, and masks. A Nigella sativa oil formulation containing 5% thymoquinone (TQ) is available on some markets and has been studied in the context of sleep disorders and stress. One traditional preparation is the mother tincture of Nigella sativa, obtained from the seeds, with attributed pharmacological activities that include anti-histamine, choleretic, carminative, and emmenagogue properties.
2. Historical and Traditional Use
Ancient Origins
Black cumin (N. sativa L.) is an annual herb that is native to southern Europe, North Africa, south and southwest Asia, and has been traditionally used since ancient times as an important medicinal plant and spice. It is one of the most ancient known domesticated plants, and its seeds were reportedly found in Tutankhamun's tomb. Black cumin is referred to by its Hebrew name "Ketzah" in the Bible in the book of Isaiah 28:25–27 and known for its curative properties.
Traditional Medicine Systems
This plant has been mentioned in the written traditional medicinal texts of major civilizations including the Ayurveda, Siddha, Unani, Greek-Roman, Malay, Tibb-e-Nabwi, and Jewish texts. In traditional remedy, N. sativa is included in the list of natural drugs in different medicine systems including Tibb-e-Nabavi (The Medicine of Prophet Muhammad), Unani Tebb, and Indian traditional medicine.
Among Muslims, it is considered one of the greatest forms of healing medicine, as it was mentioned that black seed is the remedy for all diseases except death in one of the Prophetic hadith. Since it became popular in the seventh century, there has never been a period in Islamic history when its use was ever banned. Throughout this time, the Black Seed has been used for healing, but also with the belief in the benefits that flow from the traditional practice of the Prophet Muhammad.
Traditional Therapeutic Applications
Black seeds and their oil have a long history of folklore usage in Indian and Arabian civilizations as food and medicine. The seeds have been traditionally used in Southeast Asian and Middle Eastern countries for the treatment of several diseases and ailments including asthma, bronchitis, rheumatism, and related inflammatory diseases.
In traditional remedy, N. sativa seeds are commonly used as a spice and carminative, and have been employed as liver tonics, diuretics, and digestive aids. It is an important drug in the Indian traditional system of medicine including Unani and Ayurveda. Black cumin seed has been widely used traditionally as a food ingredient and herbal remedy for the treatment of many inflammatory and allergic diseases in African, Arab, and Indian nations, especially in southwest Asia.
3. Chemical Composition and Active Constituents
Fixed Oil Fatty Acids
The oil contains approximately 50–60% linoleic acid (omega-6), 20–24% oleic acid (omega-9), and the bioactive compound thymoquinone (0.5–2% of total oil content). The oil also contains palmitic acid and trans-anethole, and other minor constituents such as nigellicine, nigellidine, nigellimine, and nigellimine N-oxide.
Volatile Oil and Terpenoids
Seed volatiles consist largely of olefinic and oxygenated monoterpenes, mainly p-cymene, thymohydroquinone, thymoquinone, γ-terpinene, and α-thujene, with lower levels of sesquiterpenes, mainly longifolene. Monoterpene composition changes during seed maturation: γ-terpinene and α-thujene are the major monoterpenes accumulated in immature seeds, with the former gradually replaced by p-cymene, carvacrol, thymohydroquinone, and thymoquinone upon seed development.
Alkaloids and Other Constituents
Chief constituents of N. sativa are thymoquinone (TQ), dithymoquinone (DTQ), thymohydroquinone (THQ), and thymol, along with p-cymene, 4-terpineol, and t-anethole. The seeds also contain carbohydrates, fats, vitamins, mineral elements, proteins, and essential amino acids. Additional constituents include nigellidine, nigellimine, nigellicine, saponins, and the water-soluble triterpene α-hederin.
The indazole alkaloids nigellidine and nigellicine are almost exclusively accumulated in the seed coat. Sugars and sugar alcohols, as well as the amino alkaloid dopamine and the saponin α-hederin, accumulate both in the seed coats and the inner seed tissues at different ratios.
Thymoquinone: The Principal Bioactive Compound
Thymoquinone is a monoterpene molecule chemically known as 2-methyl-5-isopropyl-1,4-benzoquinone, abundantly present in the seeds of Nigella sativa L. Among its many active constituents, TQ is the most abundant constituent of the volatile oil of N. sativa seeds, and it is the constituent to which most properties of this herb are attributed.
Thymoquinone has been reported to possess potent lipophilicity and limited bioavailability and exhibits light and heat sensitivity. TQ can be sensitive to external factors such as light and is unstable in alkaline media, which limits its direct pharmaceutical applicability. To mitigate these drawbacks and increase bioavailability, formulations based on nanocarriers (e.g., liposomes or lipid nanoparticles) have been proposed.
In analyses of commercial black seed oil products, TQ content varied from 3.08 to 809.4 mg/100 g (mean), indicating significant variability among products.
4. Mechanisms of Action
Anti-Inflammatory Pathways
Preclinical investigations have demonstrated that thymoquinone modulates key signaling pathways — such as NF-κB, MAPK, and PI3K/AKT — leading to attenuation of oxidative stress, suppression of pro-inflammatory cytokines, and induction of apoptosis in malignant cells.
TQ exhibits significant anti-inflammatory effects by inhibiting the NF-κB pathway, reducing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Additionally, TQ activates the Nrf2 pathway, enhancing the expression of antioxidant enzymes and reducing oxidative stress.
Because numerous effects modulated by TQ can be linked to interference with NF-κB signaling, research has investigated in detail the effect of this quinone on the NF-κB pathway. TQ has been found to suppress tumor necrosis factor–induced NF-κB activation in a dose- and time-dependent manner and to inhibit NF-κB activation induced by various carcinogens and inflammatory stimuli.
Antioxidant Mechanisms
N. sativa protects against oxidative stress via different mechanisms including inhibition of lipid peroxidation, increment in total thiol content and glutathione level, and radical scavenging, in addition to increasing the activity of superoxide dismutase, glutathione transferase, glutathione peroxidase, and catalase, as well as inhibition of NF-κB activity and inhibition of both cyclooxygenase and lipoxygenase.
TQ exerts its anti-inflammatory and antioxidant effects via several molecular pathways, including the release of cytokines and the activation of cyclooxygenase-2 (COX-2), nuclear factor erythroid 2-related factor 2 (Nrf2), PI3K/AKT, and NF-κB.
Immunomodulatory Activity
NF-κB comprises a family of ubiquitously expressed eukaryotic transcription factors critically involved in immune regulation. The anti-inflammatory effects of N. sativa and TQ, both in vitro and in vivo, are evident, extending to well-documented anti-tumor and anti-microbial properties. Increasing levels of glutathione appears to be one mechanism underlying the beneficial effects of TQ against inflammatory disorders, though other mechanisms are also in play.
Antimicrobial Activity
N. sativa seeds effectively inhibit intestinal parasites and show moderate activity against some bacteria, including Bacillus subtilis and Staphylococcus aureus. Thymoquinone exhibits minimum inhibitory concentrations (MICs) of 8–16 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA) and an MIC of 0.25 µg/mL against drug-resistant mycobacteria. Quercetin, another constituent, shows a MIC of 2 mg/mL against oral pathogens such as Streptococcus mutans.
5. Scientific Evidence by Area of Use
5.1 Metabolic Syndrome, Glycemic Control, and Lipid Profiles
N. sativa has been used in traditional medicine, and several studies have been performed in the last decades to reveal the effects of it on different medical disorders such as diabetes, dyslipidemia, hypertension, and obesity.
A 2024 systematic review of RCTs assessing N. sativa in metabolic syndrome found: Six out of 8 randomised controlled trials (n = 776) demonstrated a significant improvement in lipid profile (p <0.05), 5 out of 7 trials (n = 701) showed a significant reduction in glycaemic indices (p <0.05), 1 out of 5 trials (n = 551) demonstrated significant improvements in blood pressure (p <0.05), and 2 out of 7 trials (n = 705) showed a significant reduction in anthropometric measurements (p <0.05). Nigella sativa has proved to have a significant positive effect on lipid profile and glycaemic index, while the results for blood pressure and anthropometric indices are less convincing, as results were inconsistent across studies.
A systematic review and meta-analysis of 17 randomized controlled trials concluded that N. sativa significantly decreases plasma lipid concentration (total cholesterol, LDL, and triglycerides), whereas HDL-C increased with the powdered form only.
A meta-analysis of 22 eligible trials on blood pressure found that: seventeen studies consisting of 1,048 participants were included in the meta-analysis, with results indicating that nigella administration could significantly reduce both systolic blood pressure (−4.58 mmHg; 95% CI: −6.22, −2.94) and diastolic blood pressure (−3.08 mmHg; 95% CI: −4.62, −1.55).
Regarding diabetes specifically, N. sativa was found to be highly potent in terms of its hypoglycemic activity when compared to placebo, based on improvement in parameters including fasting blood glucose (FBG), postprandial blood glucose (PPBG), HbA1c, HOMA-IR, and HOMA-β. The compound TQ in combination with a daily dose of metformin demonstrated a greater reduction in the levels of HbA1c and blood glucose compared to metformin alone.
An overview of systematic reviews and meta-analyses confirmed: N. sativa has the potential to improve different clinical outcomes, such as blood glucose, inflammatory markers, oxidative stress factors, serum lipids, blood pressure, liver and kidney parameters, and even asthma indicators. However, there are certain limitations in reporting and methodological quality, and future studies should improve the administration process. The clinical efficacy of N. sativa needs to be confirmed in high-quality, large-sample RCTs to generate more evidence-based clinical practice.
Evidence strength: Moderate. Multiple RCTs and meta-analyses support modest improvements in lipid profiles and glycemic indices. Blood pressure and anthropometric effects are less consistent. Trials are generally small and short in duration, limiting definitive conclusions.
5.2 Respiratory Disease and Allergy
In experimental and clinical studies, antioxidant, immunomodulatory, anti-inflammatory, antihistaminic, antiallergic, antitussive, and bronchodilatory properties of N. sativa different extracts, fractions, and constituents have been demonstrated.
In adult patients with asthma, supplementary or single administration of N. sativa seed (1–2 g/day), boiled extract (50–100 mg/kg), or oil (1 g/day) for 3–12 weeks significantly improved asthma symptoms and pulmonary function tests, while in some experiments, non-significant effects on some variables including MEF25 and FEV1 were observed.
Fourteen preclinical studies described multiple effects of N. sativa in animal or cellular models of asthma, including bronchodilation, anti-histaminic, anti-inflammatory, anti-leukotrienes, and immunomodulatory effects. Seven clinical studies showed improvements in different asthma outcomes including symptoms, pulmonary function, and laboratory parameters.
All reviewed studies demonstrated that supplementation or treating patients with N. sativa seed (25–250 mg/kg/day) or oil (25 µl–0.5 ml/day) for 15–30 days alleviates symptoms of allergic rhinitis and decreases body temperature in allergic patients. These effects may be related to different immunomodulatory properties of the plant, including enhancing the phagocytic and intracellular killing activities of PMN and increment of CD8 counts, as well as antihistaminic activities of N. sativa lipid- and water-soluble constituents.
One RCT evaluated the use of N. sativa over a 3-month period: the daily intake of 15 mL/kg of 0.1% N. sativa boiled extract led to more impressive improvements in pulmonary function test parameters and alleviation of asthma symptoms than the intake of a placebo solution.
A clinical study in adolescents with partially controlled or uncontrolled asthma: a randomized controlled trial was conducted from September 2023 to August 2024. A total of 96 adolescents aged 12–18 years with partially controlled or uncontrolled asthma were enrolled, divided into two equal groups (n = 48 each). The intervention group received 500 mg Nigella sativa capsules twice daily for 12 weeks alongside standard asthma therapy, while the control group continued standard therapy alone.
Evidence strength: Promising but preliminary. Clinical evidence for respiratory and allergic disorders is supported by multiple smaller RCTs with generally positive directional findings, but trials are heterogeneous in design, dose, and population. Larger, standardized trials are needed.
5.3 Antimicrobial Activity
Black seed's antimicrobial effects include those on gram-negative and gram-positive bacteria, viruses, parasites, Schistosoma, and fungal pathogens.
In the area of anti-parasitic effects, in a study conducted on children who were infected with cestodes, the efficacy of a single oral administration of N. sativa powdered seeds and ethanolic extract (40 mg/kg body weight) was proven to reduce the percentage of fecal eggs per gram, confirming an anti-cestodal effect.
In a candidiasis study, in a RCT in which 100 infected women were included, black seed capsules (500 mg twice daily) used together with clotrimazole vaginal cream were compared against placebo capsules combined with the same cream. After a 7-day treatment, the black seed capsules used with clotrimazole vaginal cream were more effective in reducing symptoms of C. albicans vaginitis, including vaginal itching and discharge.
Nigella sativa was also shown to possess anti-viral activity against hepatitis-C infection in patients with type 2 diabetes. In a single-arm pilot study, the administration of N. sativa (450 mg of oil capsules three times daily for three months) markedly decreased the viral load.
Evidence strength: Preclinical evidence is extensive. Human clinical data is limited and consists largely of small, single trials. More rigorous RCTs are required before conclusions can be drawn about antimicrobial utility in human disease.
5.4 Anticancer Properties
N. sativa or TQ anticancer activity has been demonstrated for blood, breast, colon, pancreatic, liver, lung, fibrosarcoma, prostate, and cervix cancer cell lines and in animal models of lung, kidney, skin, colon, and breast cancer.
The beneficial organoprotective activities of thymoquinone in experimental animal models of different human diseases are attributed to potent anti-oxidant and anti-inflammatory properties. Thymoquinone has also been shown to alter numerous molecular and signaling pathways in many inflammatory and degenerative diseases including cancer.
TQ, a monoterpene quinone, has emerged as a key therapeutic compound with various pharmacological activities and lower toxicity compared to conventional chemotherapy.
Evidence strength: Mostly preclinical (in vitro and animal studies). As of current available literature, there are no robust human RCTs demonstrating anticancer efficacy of black seed or TQ. Human clinical evidence in oncology remains to be established.
5.5 Neurological and Cognitive Effects
A suggestion has been made that N. sativa and TQ utilization could prevent many disorders, including neurobehavioral and kidney and liver disorders.
Thymoquinone, with its lower molecular weight and ability to cross the blood-brain barrier, shows promising physicochemical characteristics for neurological drug development.
Evidence strength: Largely preclinical. Human studies on cognitive or neurological outcomes are very limited and must be regarded as preliminary.
5.6 Organ Protection (Hepatoprotective, Nephroprotective)
According to several lines of evidence, the protective effects of N. sativa and its main constituent in different tissues including brain, heart, liver, kidney, and lung have been demonstrated against some toxic agents, either natural or chemical toxins, in animal studies.
These effects suggest a potential role of N. sativa in the management of oxidative stress in diseases such as aging, diabetes mellitus, ischemic/reperfusion (I/R) injury, seizure, and hematotoxicity.
Evidence strength: Mostly animal/preclinical. Human evidence for hepatoprotective and nephroprotective effects is limited and inconclusive.
5.7 Opioid Dependence and Withdrawal
Based on reviewed research, TQ was effective in reducing the adverse health consequences associated with substance abuse such as withdrawal symptoms, tolerance, and cell damage. TQ has been identified as a potential drug that could complement the currently available drugs in substance abuse therapies.
There is also clinical trial support, although preliminary, for the use of black seed in people withdrawing from, and trying to abstain from, opioids.
Evidence strength: Very preliminary. Largely preclinical and small human studies. Not sufficient to support a clinical recommendation without further large-scale trials.
6. Body Systems and Health Areas Associated With Black Seed
A broad spectrum of pharmacological actions has been established for N. sativa, which include antioxidant, antidiabetic, anticancer, antitussive, immunomodulator, analgesic, antimicrobial, anti-inflammatory, spasmolytic, and bronchodilator effects.
Taken together, the peer-reviewed literature associates N. sativa with the following body systems and health domains:
- Cardiovascular and Metabolic: Blood pressure reduction, lipid lowering, glycemic control in type 2 diabetes, and metabolic syndrome support, as evidenced by multiple clinical RCTs and meta-analyses.
- Respiratory and Immune: Antioxidant, immunomodulatory, anti-inflammatory, antihistaminic, antiallergic, antitussive, and bronchodilatory properties have been demonstrated; clinical studies also showed bronchodilatory and preventive properties in asthmatic patients.
- Gastrointestinal: Gastroprotective properties have been established in preclinical studies.
- Hepatic and Renal: Hepatoprotective and renal protective activities demonstrated primarily in animal models.
- Antimicrobial: Activity against bacteria, fungi, viruses, and parasites in vitro and in limited clinical settings.
- Dermatological: Small-scale studies have shown that black seed oil may help with eczema, psoriasis, and acne.
7. Dosage Forms and Doses Reported in Studies
Black seed is typically taken in the form of an oil or a ground powder, taken orally at a dosage of 1 to 3 grams daily.
The following doses have been reported in specific clinical studies and reviews:
- In adult asthma patients: seed 1–2 g/day, boiled extract 50–100 mg/kg, or oil 1 g/day for 3–12 weeks.
- For allergic rhinitis: seed 25–250 mg/kg/day or oil 25 µl–0.5 ml/day for 15–30 days.
- In glycemic and lipid studies: capsules of crushed seeds containing 500 mg, administered in two divided daily doses (total 2.0 g/day) for 4 weeks.
- In an adolescent asthma RCT: 500 mg N. sativa capsules twice daily (total 1,000 mg/day) for 12 weeks alongside standard asthma therapy.
- In a vaginal candidiasis RCT: 500 mg capsules twice daily for 7 days, combined with clotrimazole vaginal cream.
- In a hepatitis-C pilot study: 450 mg of N. sativa oil capsules three times daily for three months.
- For Hashimoto's thyroiditis (single small study, n=40): 2,000 mg/day of powdered black seed for 8 weeks.
- In a Phase I safety study: a black seed oil formulation with 5% TQ (10 mg TQ in the daily dosage; 200 mg formulation total) was confirmed as safe in 35 healthy volunteers over 90 days versus placebo.
As a culinary spice, black seeds contribute trace amounts of thymoquinone and other bioactive compounds, but the quantities used in cooking are typically far below the doses studied in clinical trials (grams per day rather than pinches of seeds).
8. Safety Considerations and Known Interactions
General Safety Profile
Research to date has confirmed the pharmacological potential of the seed of Nigella sativa, its oil, and extracts of some of its bioactive constituents, and it has been found that the use of Black Seed is relatively safe.
A subchronic (90-day) repeated dose toxicity study in Wistar rats according to OECD guidelines revealed a TQ no-observed-adverse-effect level (NOAEL) of 5 mg/kg. Upon conversion to human dosage, the safe daily TQ dosage was calculated to be below 48.6 mg per adult.
Oral doses of black seed oil of 15 and 25 mL/kg over four weeks induced changes in the histological structure of the renal cortex and, to a lesser extent, of the liver cells in animal studies.
TQ Bioavailability and Formulation Variability
In commercial products, TQ content varied from 3.08 to 809.4 mg/100 g, indicating significant variability among products. A dose of 4 mL per day of a high-TQ oil contains approximately 30 mg TQ, which is considered unlikely to be harmful. Based on the literature, a safe daily TQ dosage appears to be below 48.6 mg per adult.
The bioavailability of TQ can be enhanced by using nanoparticulate drug delivery systems.
Cytochrome P450 Enzyme Interactions
In an in vivo study, administration of N. sativa for one week resulted in a significant reduction in gene expression, as well as metabolic activity, of CYP2D. A similar study, using tolbutamide as a substrate, showed that its oil extract had considerable inhibitory effects against CYP2C11.
When N. sativa was co-administered with cyclosporine in an animal model, the oral bioavailability of cyclosporine was significantly reduced. These findings suggest the possibility of pharmacokinetic interactions with drugs metabolized by CYP enzymes.
Interaction With Warfarin
Kinetic analysis indicated that thymoquinone exhibited competitive inhibition on warfarin 7-hydroxylation, with a Ki value of 3.50 ± 0.44 μM. Food-drug interaction risk prediction suggested that co-administration of thymoquinone (>18 mg/day) or dietary supplements containing thymoquinone (N. sativa >1 g/day) may pose a risk when combined with warfarin.
Anticoagulant and Antiplatelet Considerations
Nigella sativa possesses significant potential in modulating blood clotting mechanisms. Thymoquinone has shown thrombolytic effects by promoting the dissolution of fibrin clots. The synergistic interaction between various bioactive compounds in Nigella sativa may contribute to its anticoagulant and thrombolytic properties. While preclinical evidence suggests promising therapeutic benefits, further clinical trials are needed to establish the safety, efficacy, and mechanisms underlying these anticoagulant and thrombolytic actions in human subjects.
Hypoglycemic Drug Interactions
Nigella sativa may lower blood sugar levels. When taken with diabetes medications, it could potentially cause blood sugar to drop too low. Careful monitoring of blood sugar levels is essential if combining these medications with nigella sativa supplements.
Antihypertensive Drug Interactions
Nigella sativa might lower blood pressure. Taking it alongside antihypertensive drugs could result in blood pressure dropping too low, and blood pressure should be closely monitored if using this combination.
Pregnancy and Uterine Activity
Administration of a dried petroleum extract of the seeds during the first ten days of pregnancy in doses equivalent to 2 g seeds/kg/day orally has been shown to inhibit the implantation process in animal studies. These animal data suggest caution regarding supplemental use during pregnancy, although the clinical implications in humans are not yet established from controlled trials.
Immunosuppressant Interactions
Black seed can increase immune system activity, potentially decreasing the effectiveness of immunosuppressant medications.
Overall Evidence Limitations
There are certain limitations in reporting and methodological quality across available trials, and future studies should improve the administration process. The clinical efficacy of N. sativa needs to be confirmed in high-quality, large-sample RCTs to generate more evidence-based clinical practice. Considering the findings of the clinical studies along with generally modest adverse effects, N. sativa has potential application in bioproduct development, but its full safety and interaction profile in humans requires further characterization.
References
- Tavakkoli A et al. Black Seed (Nigella sativa) and its Constituent Thymoquinone as an Antidote or a Protective Agent Against Natural or Chemical Toxicities. Iranian Journal of Pharmaceutical Research, 2017. PMC5963642
- Hosseinzadeh H et al. Review on Clinical Trials of Black Seed (Nigella sativa) and Its Active Constituent, Thymoquinone. Journal of Pharmacopuncture, 2017. PMC5633670
- Black Seeds (Nigella sativa) Medical Application and Pharmaceutical Perspectives. PMC10353664
- Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin. PMC5613109
- Distribution of Primary and Specialized Metabolites in Nigella sativa Seeds. PMC6268483
- A Review on Therapeutic Potential of Nigella sativa: A Miracle Herb. PMC3642442
- Effects of Nigella sativa Supplementation on Blood Parameters and Anthropometric Indices in Adults: A Systematic Review on Clinical Trials. PMC5122217
- Effect of Nigella sativa Supplementation over a One-Year Period on Lipid Levels, Blood Pressure and Heart Rate in Type-2 Diabetic Patients. PMC6148980
- Nigella sativa and Health Outcomes: An Overview of Systematic Reviews and Meta-Analyses. PMC10086143
- Systematic Review of Randomized Controlled Trials in Uses of Nigella sativa (Black Seed) in Metabolic Syndrome. PubMed 39002164
- Nigella sativa Improves Glucose Homeostasis and Serum Lipids in Type 2 Diabetes: A Systematic Review and Meta-analysis. PubMed 29154069
- Nigella sativa L. and Its Active Compound Thymoquinone in the Clinical Management of Diabetes: A Systematic Review. PMC9602931
- Clinical and Experimental Effects of Nigella sativa and Its Constituents on Respiratory and Allergic Disorders. PMC6526035
- Medicinal Benefits of Nigella sativa in Bronchial Asthma: A Literature Review. PubMed 30166900
- Screening of Thymoquinone Content in Commercial Nigella sativa Products to Identify a Promising and Safe Study Medication. PMC9460610
- Inhibition of Cytochrome P450 Enzymes by Thymoquinone in Human Liver Microsomes. PMC6035319
- Anti-inflammatory Effects of Thymoquinone and Its Protective Effects Against Several Diseases. ScienceDirect, Biomedicine & Pharmacotherapy, 2021
- Immunomodulatory and Anti-inflammatory Action of Nigella sativa and Thymoquinone: A Comprehensive Review. ScienceDirect, 2015
- Targeting Nuclear Factor-κB Activation Pathway by Thymoquinone. Molecular Cancer Research, AACR, 2008
- How Thymoquinone from Nigella sativa Accelerates Wound Healing through Multiple Mechanisms and Targets. PMC10670084
- Antimicrobial Properties and Therapeutic Potential of Bioactive Compounds in Nigella sativa: A Review. PMC11510594
- Nigella sativa: A Comprehensive Review of Its Therapeutic Potential, Pharmacological Properties, and Clinical Applications. MDPI International Journal of Molecular Sciences, 2024
- The Use of Nigella sativa in Cardiometabolic Diseases. PMC10886913
- Thymoquinone: From Nigella sativa to a Protective Pharmacological Compound in Managing Opioid Dependence. PMC7395189
- Potential Food-Drug Interaction Risk of Thymoquinone with Warfarin. ScienceDirect, 2022
- Safety Evaluation of Phytovagex, a Pessary Formulation of Nigella sativa, on Pregnant Rats. PMC4884224
- History and Traditional Uses of Black Seeds (Nigella sativa). ScienceDirect Book Chapter, 2022
- Black Seed: Benefits, Dosage, and Side Effects. Examine.com
- Therapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways. PMC4052177
- Thymoquinone, a Potential Adjunctive Treatment for Ulcerative Colitis. PMC12413807
Volver